Searched for
EMCURE PHARMACEUTICALS LTD
Union Bank of India among 7 stocks flashing bullish signals, hinting at a possible uptrendOn July 20, seven stocks in the Nifty500 appeared on the 'White Marubozu' bullish scanner, according to StockEdge's technical scan data. Th...- Stocks in news: CDSL, Adani Energy, L&T, Adani Total Gas, Emcure PharmaMarkets declined on Monday due to disappointing earnings and geopolitical worries. CDSL faced a Rs 1 crore penalty from Sebi for cybersecur...
- Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatmentEmcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treati...
- Reliance Industries, Groww and MTAR Technologies among stocks bought and sold by mutual funds in JuneMutual funds invested Rs 50,600 crore in stocks during June. They significantly bought JSWInfra, Bajaj Finance, and HDFC Bank. Conversely, ...
- For investors with high risk-appetite: 5 mid-cap stocks from different sectors with upside potential of up to 21%Brace for trouble. The US-Iran conflict now appears to be gaining in intensity and the commodities market is taking the current spiral of v...
- Ahead of Market: 10 things that will decide D-Street action on MondayIndian markets closed marginally higher on Thursday after a volatile expiry session, with the Sensex rising 109 points to 77,100.47 and the...
- Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...
- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- Delhivery elevates six executives to C-suite roles amid expansion pushLogistics firm Delhivery has promoted six senior executives to C-suite positions. These appointments support the company's expansion across...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Emcure eyes India growth, global deals amid strong demandEmcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...
- Mauritius-based entity sells Rs 289 crore worth shares in Emcure Pharmaceuticals via block deal; Norges Bank acquirerEmcure Pharmaceuticals saw a significant block deal where BC Investments IV Limited sold 18 lakh shares for Rs 289 crore to Norges Bank. Th...
- Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug LenacapavirEmcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention a...
- Emcure Pharmaceuticals IPO share allotment likely on Monday. Here's how you can check the status.
- Emcure Pharmaceuticals IPO booked nearly 68 times so far on Day 3. Check GMP and other detailsEmcure Pharmaceuticals IPO sees strong demand with oversubscription. Anchor investors include top names. Company engaged in global pharmace...
- Emcure Pharmaceuticals IPO booked nearly 5x so far on Day 2. Check GMP and other detailsEmcure Pharmaceuticals' IPO has been oversubscribed nearly three times as of Thursday, the second day of bidding. The bidding concludes on ...
- Emcure Pharmaceuticals IPO: 10 things to know before subscribing to the issueEmcure Pharmaceuticals IPO is scheduled to open for subscription on July 3 and will close on July 5. The company aims to raise approximatel...
- Emcure Pharma announces price band for Rs 1,952-crore IPO at Rs 960-1,008/share. Check GMP, other detailsEmcure Pharmaceuticals has announced its initial public offering (IPO) with a price band of Rs 960 to Rs 1,008 per equity share. The subscr...
- Emcure Pharmaceuticals receives SEBI nod for its IPO launchEmcure Pharmaceuticals received SEBI nod for IPO launch after filing DRHP in December 2023. The IPO includes equity shares and an Offer of ...
- Emcure Pharmaceuticals acquires Canadian company and its marketing arm MarcanMarcan Pharma has over 60 approved products that are mainly available via McKesson and Kohl & Frisch, among other wholesalers, it claimed.
Load More
